GOODWILL IPRANDD AND OTHER INTANGIBLE ASSETS, NET (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET
Accumulated impairment losses	$ 0		$ 0
Finite-lived intangible assets
Intangible assets, gross	194,427,000		194,427,000		194,427,000
Intangible assets, net	142,594,000		142,594,000		152,830,000
Amortization expense	5,200,000	5,200,000	10,200,000	10,400,000
Estimated aggregate amortization of intangible assets
Remainder of 2013	10,365,000		10,365,000
2014	20,729,000		20,729,000
2015	20,729,000		20,729,000
2016	19,449,000		19,449,000
2017	18,210,000		18,210,000
2018 and thereafter	53,112,000		53,112,000
Total	142,594,000		142,594,000		152,830,000
Patents
Finite-lived intangible assets
Intangible assets, gross	2,627,000		2,627,000		2,627,000
Less: accumulated amortization	(2,462,000)		(2,462,000)		(2,431,000)
Acquired technology rights
Finite-lived intangible assets
Intangible assets, gross	191,800,000		191,800,000		191,800,000
Less: accumulated amortization	(49,371,000)		(49,371,000)		(39,166,000)
Bevenopran (formerly known as CB-5945)
Acquired IPR&D
Acquired IPR&D	78,700,000		78,700,000
Ceftolozane/tazobactam (formerly known as CXA-201)
Acquired IPR&D
Acquired IPR&D	194,000,000		194,000,000
Ceftolozane/tazobactam (formerly known as CXA-201) for HABP and VABP
Acquired IPR&D
Acquired IPR&D	174,000,000		174,000,000
Ceftolozane/tazobactam (formerly known as CXA-201) for cUTI and cIAI
Acquired IPR&D
Acquired IPR&D	$ 20,000,000		$ 20,000,000